Last reviewed 2026-05-15 · How we verify

AQ280 Tablet for Oral Suspension

AQILION AB · Phase 1 active Small molecule

AQ280 Tablet for Oral Suspension is a Small molecule drug developed by AQILION AB. It is currently in Phase 1 development.

At a glance

Generic name	AQ280 Tablet for Oral Suspension
Sponsor	AQILION AB
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AQ280 Tablet for Oral Suspension CI brief — competitive landscape report
AQ280 Tablet for Oral Suspension updates RSS · CI watch RSS
AQILION AB portfolio CI

Frequently asked questions about AQ280 Tablet for Oral Suspension

What is AQ280 Tablet for Oral Suspension?

AQ280 Tablet for Oral Suspension is a Small molecule drug developed by AQILION AB.

Who makes AQ280 Tablet for Oral Suspension?

AQ280 Tablet for Oral Suspension is developed by AQILION AB (see full AQILION AB pipeline at /company/aqilion-ab).

What development phase is AQ280 Tablet for Oral Suspension in?

AQ280 Tablet for Oral Suspension is in Phase 1.

Manufacturer: AQILION AB — full pipeline
Compare: AQ280 Tablet for Oral Suspension vs similar drugs
Pricing: AQ280 Tablet for Oral Suspension cost, discount & access